Journal of pediatric hematology/oncology
-
J. Pediatr. Hematol. Oncol. · Mar 2021
Multimodal Analgesic Plan for Children Undergoing Chimeric 14.18 Immunotherapy.
Immunotherapy with the chimeric 14.18 anti-GD2 antibody (ch14.18) is associated with severe neuropathic pain. Different analgesic modalities have been employed, but pain management remains challenging and side effects such as desaturation, bradycardia, and hypotension have been reported. ⋯ Morphine consumption was similar to other studies. Our results suggest that this regimen may be a valid analgesic option in children undergoing ch14.18 infusion.